RecruitingNot applicableNCT04331769
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Studying Dilated cardiomyopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ancora Heart, Inc.
- Principal Investigator
- Martin B Leon, MDColumbia University
- Intervention
- AccuCinch Ventricular Restoration System(device)
- Enrollment
- 400 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2030
Study locations (30)
- Grandview Medical Group Research, LLC, Birmingham, Alabama, United States
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Phoenix Cardiovascular Research Group, Phoenix, Arizona, United States
- Tucson Medical Center, Tucson, Arizona, United States
- Baptist Health Heart Failure & Transplant Institute, Little Rock, Arkansas, United States
- University of California San Diego, La Jolla, California, United States
- Scripps Health, La Jolla, California, United States
- University of Southern California, Los Angeles, California, United States
- Kaiser Permanente San Francisco, San Francisco, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Colorado, Aurora, Colorado, United States
- Hartford Health, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Medstar Health Research Institute, Washington D.C., District of Columbia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04331769 on ClinicalTrials.govOther trials for Dilated cardiomyopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07137338A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated CardiomyopathyRocket Pharmaceuticals Inc.
- RECRUITINGNCT07293338Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated CardiomyopathySecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1NCT07241104A Study of AZD4063 in PLN R14del Dilated CardiomyopathyAstraZeneca
- RECRUITINGNANCT07359690Multimodal Analysis of Endomyocardial BiopsiesUniversity Hospital, Essen
- RECRUITINGPHASE1NCT06464588A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)Emory University
- RECRUITINGNANCT06922851Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06741995Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated CardiomyopathyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT06688396Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)Lancaster General Hospital